{"id":26788,"date":"2021-09-23T12:21:27","date_gmt":"2021-09-23T10:21:27","guid":{"rendered":"https:\/\/www.transgene.com\/?page_id=26788"},"modified":"2026-01-08T18:15:25","modified_gmt":"2026-01-08T17:15:25","slug":"publications-fr","status":"publish","type":"page","link":"https:\/\/www.transgene.com\/fr\/publications-fr\/","title":{"rendered":"Publications"},"content":{"rendered":"\n<div id=\"tetContainer\" class=\"wp-block-uagb-container uagb-block-ec6f09b8 alignfull uagb-is-root-container\">\n<div class=\"wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"tgTetContainer\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"degHaut\">\n<div class=\"wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"degbas\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"ongletBas\">\n<h1>Publications<\/h1>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div id=\"cont1200\" class=\"wp-block-uagb-container uagb-block-80162e23 alignfull uagb-is-root-container\"><div class=\"uagb-container-inner-blocks-wrap\">\n<div class=\"maxWidth  mamouchka-Parent eplus-wrapper wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"mamouchkaChild eplus-wrapper wp-block-columns alignfull is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"catalistblock eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h2>&nbsp;<\/h2>\n<h2 class=\"cgDeg\" style=\"color: var(--tgo3); text-align: left;\">Classement par produit<\/h2>\n<p>&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-uagb-tabs uagb-block-e7a53760 uagb-tabs__wrap uagb-tabs__hstyle1-desktop uagb-tabs__hstyle3-tablet uagb-tabs__stack1-mobile uagb-tabs__vstyle6-mobile\" data-tab-active=\"0\" id=\"CP-produit\"><ul class=\"uagb-tabs__panel uagb-tabs__align-left\" role=\"tablist\"><li class=\"uagb-tab uagb-tabs__active\" role=\"none\"><a href=\"#uagb-tabs__tab0\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"0\" role=\"tab\"><div>TG4050<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab1\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"1\" role=\"tab\"><div><em>myvac<\/em>\u00ae<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab2\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"2\" role=\"tab\"><div><meta charset=\"utf-8\">BT-001<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab3\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"3\" role=\"tab\"><div>TG6050<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab4\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"4\" role=\"tab\"><div>Autres<\/div><\/a><\/li><\/ul><div class=\"uagb-tabs__body-wrap\">\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-0 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab0\" id=\"CP-produit\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\" title=\"A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al. <br>Article disponible sur <a href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\"><strong>le site de Nature Communications<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/s41467-026-76667-1.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\" title=\"TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">K. Bidet-Huang\n<br>World Vaccine Congress 2026<\/br>\n&#8211; T\u00e9l\u00e9charger la <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" title=\"Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>medRxiv<\/br>\nPrepublication disponible sur le site <a href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" ><strong>medRxiv <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/medRxiv_TG4050.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" title=\"VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">B. Grellier, et al.\n<br>ESMO-AI 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" ><strong>site de l&rsquo;ESMO-AI<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250901_ESMO-AI_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMOAI2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" title=\"Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>SITC 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" ><strong> site du JITC <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/SITC2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251107_TG4050_SITC2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" title=\"Contribution de la levure \u00e0 la virologie synth\u00e9tique\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Contribution de la levure \u00e0 la virologie synth\u00e9tique<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Rey, et al.\n<br>Virologie 2025<\/br>\nArticle disponible sur le <a href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" ><strong>site de JLE<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Rey-contribution-of-yeast-to-synthetic-virology-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" title=\"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>ASCO 2025<\/br>\nAbstract disponible sur le  <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" ><strong>site de l&rsquo;ASCO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250522_TG4050_ASCO2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ASCO2025_TG4050.pdf\"><strong>Pr\u00e9sentation Orale Rapide<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" title=\"Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.<\/p>\n<p>SITC 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" ><strong>site du SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" title=\"Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Lalanne, et al.<\/p>\n<p>AACR 2024&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" ><strong>AACR website<\/strong><\/a>\n&#8211; Download the <a href=\"\nhttps:\/\/www.transgene.com\/wp-content\/uploads\/20240209_AACR2024_TG4050_poster.pdf\"><strong>poster <\/strong><\/a><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" title=\"Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.<\/p>\n<p>ASCO 2023&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" ><strong>ASCO website<\/strong><\/a>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230525_TG4050_ASCO_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_ASCO2023_Safety_Immunogenicity_TG4050.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">A. Lalane et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Immunogenicity_Activity_TG4050_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)<\/div> <div class=\"lcp_content\">\n<p>JP Delord, et al.<br \/>ASCO 2022 <br \/>Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong> <\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_NEC_TG4050_ASCO2022_poster.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong> <\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients<\/div> <div class=\"lcp_content\">\n<p>MS Block et al.<br \/>AACR 2022<br \/>Read the abstract <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/20200\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_TG4050_AACR2022_poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" title=\"Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine<\/div> <\/a><div class=\"lcp_content\"><p>B. Mallone et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" title=\"Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer<\/div> <\/a><div class=\"lcp_content\"><p>K. Bendjama, E. Qu\u00e9m\u00e9neur<br \/>\nHuman Vaccines and Immunotherapeutics, August 2017 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><\/ul>\n\n\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-1 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab1\" id=\"CP-produit\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\" title=\"A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al. <br>Article disponible sur <a href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\"><strong>le site de Nature Communications<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/s41467-026-76667-1.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\" title=\"TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">K. Bidet-Huang\n<br>World Vaccine Congress 2026<\/br>\n&#8211; T\u00e9l\u00e9charger la <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" title=\"Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>medRxiv<\/br>\nPrepublication disponible sur le site <a href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" ><strong>medRxiv <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/medRxiv_TG4050.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" title=\"VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">B. Grellier, et al.\n<br>ESMO-AI 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" ><strong>site de l&rsquo;ESMO-AI<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250901_ESMO-AI_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMOAI2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" title=\"Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>SITC 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" ><strong> site du JITC <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/SITC2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251107_TG4050_SITC2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" title=\"Contribution de la levure \u00e0 la virologie synth\u00e9tique\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Contribution de la levure \u00e0 la virologie synth\u00e9tique<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Rey, et al.\n<br>Virologie 2025<\/br>\nArticle disponible sur le <a href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" ><strong>site de JLE<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Rey-contribution-of-yeast-to-synthetic-virology-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" title=\"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>ASCO 2025<\/br>\nAbstract disponible sur le  <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" ><strong>site de l&rsquo;ASCO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250522_TG4050_ASCO2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ASCO2025_TG4050.pdf\"><strong>Pr\u00e9sentation Orale Rapide<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" title=\"Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.<\/p>\n<p>SITC 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" ><strong>site du SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" title=\"Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Lalanne, et al.<\/p>\n<p>AACR 2024&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" ><strong>AACR website<\/strong><\/a>\n&#8211; Download the <a href=\"\nhttps:\/\/www.transgene.com\/wp-content\/uploads\/20240209_AACR2024_TG4050_poster.pdf\"><strong>poster <\/strong><\/a><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" title=\"Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.<\/p>\n<p>ASCO 2023&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" ><strong>ASCO website<\/strong><\/a>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230525_TG4050_ASCO_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_ASCO2023_Safety_Immunogenicity_TG4050.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">A. Lalane et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Immunogenicity_Activity_TG4050_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)<\/div> <div class=\"lcp_content\">\n<p>JP Delord, et al.<br \/>ASCO 2022 <br \/>Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong> <\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_NEC_TG4050_ASCO2022_poster.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong> <\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients<\/div> <div class=\"lcp_content\">\n<p>MS Block et al.<br \/>AACR 2022<br \/>Read the abstract <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/20200\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_TG4050_AACR2022_poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" title=\"Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine<\/div> <\/a><div class=\"lcp_content\"><p>B. Mallone et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-myvac.pdf\" title=\"myvac\u2122 Viral based vaccine for personalized neoantigen-directed cancer therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>myvac\u2122 Viral based vaccine for personalized neoantigen-directed cancer therapy<\/div> <\/a><div class=\"lcp_content\"><p>Christian Ottensmeier, et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-myvac.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/a><\/p>\n<p>Collaboration between Transgene \u2013 University of Southampton, United Kingdom \u2013 La Jolla Institute for allergy and immunology, USA \u2013 University of Copenhagen, Denmark<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" title=\"Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer<\/div> <\/a><div class=\"lcp_content\"><p>K. Bendjama, E. Qu\u00e9m\u00e9neur<br \/>\nHuman Vaccines and Immunotherapeutics, August 2017 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-2 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab2\" id=\"CP-produit\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=955P\" title=\"Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Lebbe, et al.\n<br>ESMO 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=955P\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_Abstract_ESMO2025.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251018_BT001_ESMO2025.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal_2\/presentation\/list?q=1024P\" title=\"Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">S. Champiat, et al.<\/p>\n<p>ESMO 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal_2\/presentation\/list?q=1024P\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_ESMO2024-2.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_ESMO2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/16993\" title=\"Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">JB Marchand et al.<\/p>\n<p>AACR 2022<\/p>\n<p>Abstract disponible sur le site de l&rsquo;<a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/16993\" ><strong>AACR<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2022_BT001_Poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-Euroocs-hle-2021-version-finale.pdf\" title=\"3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses<\/div> <\/a><div class=\"lcp_content\"><p><br \/>H\u00e9l\u00e8ne L\u00ea et al.<br \/>EUROoCS 2021<br \/>Download the Poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-Euroocs-hle-2021-version-finale.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p>Jean-Baptiste Marchand et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" title=\"Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine<\/div> <\/a><div class=\"lcp_content\"><p>H. Le et al.<br \/>\nEUROoCS 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p><br \/>Jean-Baptiste Marchand et al.<br \/>AACR 2020<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_Transgene_BT-001_Immuno_Onco_2020.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p>Marchand, Semmrich, Fend et al.<br \/>\nImmuno-Oncology summit<br \/>\nDownload the poster<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_Transgene_BT-001_Immuno_Onco_2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-3 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab3\" id=\"CP-produit\">\n<p class=\"eplus-wrapper wp-block-paragraph\">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.<\/p>\n\n\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/static1.squarespace.com\/static\/56dee71e555986fb3ae583e2\/t\/66db4e7cb9451f7aac7fcd10\/1725648512282\/CICON24+Abstracts+FINAL+090524+v4.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">L.Fend, et al.<\/p>\n<p>ESMO 2024&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/static1.squarespace.com\/static\/56dee71e555986fb3ae583e2\/t\/66db4e7cb9451f7aac7fcd10\/1725648512282\/CICON24+Abstracts+FINAL+090524+v4.pdf\" ><strong>CICON website<\/strong><\/a>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/CICON2024_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/CICON2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/jitc\/12\/7\/e009302.full.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">F. Azar et al.\n<br>Journal for ImmunoTherapy of Cancer July 2024<\/br>\nArticle disponible sur le <a href=\"https:\/\/jitc.bmj.com\/content\/jitc\/12\/7\/e009302.full.pdf\" ><strong>site du JITC<\/strong><\/a>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_TG6050_TME_remodeling_poster.pdf\" title=\"TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">JB. Marchand et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_TG6050_TME_remodeling_poster.pdf\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-4 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab4\" id=\"CP-produit\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\" title=\"PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">J. Foloppe et al.\n<br>SITC 2026<br>\n&#8211; Abstract disponible sur le site du <a href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\"><strong>SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261103_SITC_Abstract.pdf\"><strong>Abstract<\/strong><\/a>&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261107_PosterSITC2026.pdf\"><strong>Poster<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\" title=\"Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Agaoua et al.\n<br>frontiers in Bioengineering and Biotechnology<br>\n&#8211; Article disponible sur le site de <a href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\"><strong>frontiers<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fbioe-14-1943548.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/isevjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jev2.70307\" title=\"Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">L. Walther, et al. <br>Article disponible sur <a href=\"https:\/\/isevjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jev2.70307\"><strong>le site de l&rsquo;ISEV<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260619_JEV_LWalther.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/infectiouscongress.com\/program\/scientific-program\/2026\/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl\" title=\"Robust Protection Against Monkeypox Virus Mediated by a Novel Cell\u2011Line\u2013Derived MVA Vaccine (TG-MVACL)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Robust Protection Against Monkeypox Virus Mediated by a Novel Cell\u2011Line\u2013Derived MVA Vaccine (TG-MVACL)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">N. Silvestre, et al. <br>World Congress on Infectious Diseases WCID 2026 Abstract disponible sur le <a href=\"https:\/\/infectiouscongress.com\/program\/scientific-program\/2026\/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl\"><strong>site du WCID<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Abstract_WCID_2026.pdf\"><strong>abstract <\/strong><\/a> &#8211; T\u00e9l\u00e9charger la<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2026_WCID_TGMVA.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_Abstract.pdf\" title=\"Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Agaoua et al.\n<br>International Oncolytic Virus Conference 2026<\/br>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_Abstract.pdf\"><strong>Abstract<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_SOVIV.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3705\" title=\"Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">P. Erbs, et al.\n<br>Cancers 2025<\/br>\nAbstract disponible sur le site <a href=\"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3705\" ><strong>MDPI<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/McGuckin-et-al-Cancers-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" title=\"Contribution de la levure \u00e0 la virologie synth\u00e9tique\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Contribution de la levure \u00e0 la virologie synth\u00e9tique<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Rey, et al.\n<br>Virologie 2025<\/br>\nArticle disponible sur le <a href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" ><strong>site de JLE<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Rey-contribution-of-yeast-to-synthetic-virology-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=1592eP\" title=\"Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>ESMO 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=1592eP\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/MVA-Safety_ASCO-2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMO2025_SafetyMVA_ePoster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fmicb-16-1656984.pdf\" title=\"TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">J. Foloppe, et al.\n<br>Frontiers in Microbiology Septembre 2025<\/br>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fmicb-16-1656984.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250807_CICON2025_Poster.pdf\" title=\"A Pseudocowpox virus vector to generate human B cell-based vaccines\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Pseudocowpox virus vector to generate human B cell-based vaccines<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Thioudellet, et al.\n<br>CICON 2025<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250807_CICON2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Utilisation de l&rsquo;analyseur xCELLigence RTCA eSight pour l&rsquo;\u00e9valuation de la nouvelle platefrome de virus oncolytique de Transgene<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper\">B. Moreau et al.<br>AFH 2025<br>T\u00e9l\u00e9charger le poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AFH2025_BaM.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>ici<\/strong><\/a><br><em>Poster pr\u00e9sentation<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT420440\" title=\"Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-na\u00efve recurrent and\/or metastatic(R\/M) HPV16-positive cervical or anogenital cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-na\u00efve recurrent and\/or metastatic(R\/M) HPV16-positive cervical or anogenital cancer<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>ASCO 2025<\/br>\nAbstract disponible sur le  <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT420440\" ><strong>site de l&rsquo;ASCO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250522_TG4001_ASCO2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ASCO2025_TG4001_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper\">E. J. West et al.<br>Clinical Cancer Research April 2025<br>Lire l&rsquo;article <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ccr-24-2498.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>ici<\/strong><\/a><br><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/iovc2024.nl\/\" title=\"TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">J. Foloppe, et al.<\/p>\n<p>IOVC 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/iovc2024.nl\/\" ><strong>site de l&rsquo;IOVC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Abstract_IOVC_2024.pdf\"><strong>abstract <\/strong><\/a>et le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_IOVC_2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.cell.com\/molecular-therapy-family\/oncology\/fulltext\/S2950-3299(24)00129-2\" title=\"Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">U. Hirigoyen, et al.<\/p>\n<p>Oncology 2024<\/p>\n<p>Article disponible sur le  <a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/oncology\/fulltext\/S2950-3299(24)00129-2\" ><strong>site Molecular Therapy Oncology<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Hirigoyen-et-al-2024.pdf\"><strong>Article <\/strong><\/a>\n<\/p>\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804923003337\" title=\"Phase Ib\/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\"> C. Le Tourneau, et al.<br\/>European Journal of Cancer, July 2023 (191)<br\/>T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804923003337\"><strong>Article<\/strong><\/a><br\/><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">H. Le et al.<br>AACR 2023<br>Download the poster <a rel=\"noreferrer noopener\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_PatientDerivedLungTumoroid_poster.pdf\" target=\"_blank\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>PoxSTG, a novel chimeric poxvirus with improved oncolytic potency<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">P. Erbs et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Novel_Chimeric_Poxvirus_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2023_TG4001_Poster.pdf\" title=\"A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>AACR 2023<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2023_TG4001_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">JM. Marchand et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Vectorized_Anti-PD1_sdAb_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">L. Walther et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_ExtracellularVesicles_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)<\/div> <div class=\"lcp_content\">\n<p>JP Delord, et al.<br \/>ASCO 2022 <br \/>Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong> <\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_NEC_TG4050_ASCO2022_poster.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong> <\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination<\/div> <div class=\"lcp_content\"><p>Rodrigo Nalio Ramos, et al.<br \/>\nClinical &amp; Translational Immunology, May 8 2022 &#8211; <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cti2.1392\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorized Treg-depleting \u03b1CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject \u00ab\u00a0cold\u00a0\u00bb tumors<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">Semmrich M, Marchand J, Fend L, et al<\/p>\n<p>Journal for ImmunoTherapy of Cancer 2022<\/p>\n<p>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/jitc.bmj.com\/content\/10\/1\/e003488\" target=\"_blank\" rel=\"noopener\"><strong>article<\/strong><\/a><br><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene-Poster-TG6002-ESMO-2021.pdf\" title=\"Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas<\/div> <\/a><div class=\"lcp_content\"><p class=\"eplus-emXPV0 eplus-wrapper\">P. Cassier et al.<br \/>\nESMO 2021<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene-Poster-TG6002-ESMO-2021.pdf\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas<\/div> <div class=\"lcp_content\"><p>K. Bendjama et al.<br \/>\nAACR 2021<br \/>\nRead the abstract <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/9325\/presentation\/4663\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/TG6002-_AACR_2021_poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33798643\/\" title=\"Immunocompetent cancer-on-chip models to assess immuno-oncology therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immunocompetent cancer-on-chip models to assess immuno-oncology therapy<\/div> <\/a><div class=\"lcp_content\"><p>Tengku Ibrahim Maulana, et al.<br \/>\nAdv Drug Deliv Rev., March 30 2021 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33798643\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC<\/div> <div class=\"lcp_content\"><p>Adrian von Witzleben, et al.<br \/>\nFront Oncol., January 26 2021 &#8211; <a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.591063\/full\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>Franck Gallardo, et al.<br>Biomedicines, November 26 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33256205\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>J\u00e9r\u00e9my B\u00e9guin, et al.<br>Molecular Therapy Oncolytics, September 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33072863\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" title=\"Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine<\/div> <\/a><div class=\"lcp_content\"><p>H. Le et al.<br \/>\nEUROoCS 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Poster-0710-AASLD-2019-TG1050-T101_Metaanalyse.pdf\" title=\"Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe\/Canada or China\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe\/Canada or China<\/div> <\/a><div class=\"lcp_content\">\n<p><br \/>Fabien Zoulim et al.<br \/>AASLD 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Poster-0710-AASLD-2019-TG1050-T101_Metaanalyse.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\"><p>Christophe Le Tourneau et al.<br \/>\nESMO 2019<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\">\n<p><br \/>Christophe Le Tourneau et al.<br \/>ESMO 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\">\n<p><br \/>Christophe Le Tourneau et al.<br \/>ESMO 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up<\/div> <div class=\"lcp_content\"><p>Diane. M. Harper, et al.<br \/>Gynecologic Oncology, April 2019 &#8211; <a href=\"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.250\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>The publication has been featured in <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30224-4\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>The Lancet Oncology<\/strong><\/a> and <a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/cervicalcancer\/79117\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Medpage Today<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up<\/div> <div class=\"lcp_content\">\n<p><br \/>Diane M. Harper, et al.<br \/>Gynecologic Oncology, April 2019 &#8211; <a href=\"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.250\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>The publication has been featured in <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30224-4\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>The Lancet Oncology<\/strong><\/a> and <a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/cervicalcancer\/79117\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Medpage Today<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism<\/div> <div class=\"lcp_content\"><p><br \/>Johann Foloppe, et al.<br \/>Molecular Therapy Oncolytics, March 2019 &#8211; <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6461584\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/11\/Poster_AASLD-2018_TG1050_COMBO_FINAL_30OCT18.pdf\" title=\"Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice<\/div> <\/a><div class=\"lcp_content\"><p>Roland Kratzer, et al.<br \/>\nAASLD, The Liver Meeting 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.30257\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>AASLD website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster_AASLD-2018_TG1050_COMBO_FINAL_30OCT18.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene &#8211; Laboratoire de Recherches Biochirurgicales, Universit\u00e9 Paris Descartes, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France &#8211; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France &#8211; H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France &#8211; Alnylam Pharmaceuticals, Cambridge, USA &#8211; The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan, China<\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment<\/div> <div class=\"lcp_content\"><p>Jean-Baptiste Marchand et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/11\/SITC-2018-Poster-Invir.IO_.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene \u2013 BioInvent International A.B, Sweden<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/11\/Poster-AASLD-2018-TG1050.02.pdf\" title=\"Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study<\/div> <\/a><div class=\"lcp_content\"><p>Claire Fournier, et al.<br \/>\nAASLD, The Liver Meeting 2018, November 2018 &#8211; Abstract available on the <strong><a href=\"https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.30257\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>AASLD website<\/strong><\/a><\/strong><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/11\/Poster-AASLD-2018-TG1050.02.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-PCPV.pdf\" title=\"Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Karola Rittner, et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-PCPV.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/TG_ASCO-Pexa-vec-poster-23-05-18-vf.pdf\" title=\"Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity<\/div> <\/a><div class=\"lcp_content\"><p>Alan Anthoney, et al.<br \/>\nASCO 2018, June 2018 &#8211; Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/TG_ASCO-Pexa-vec-poster-23-05-18-vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0196815\" title=\"A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis<\/div> <\/a><div class=\"lcp_content\"><p>Stephane Leung-Theung-Long, et al.<br \/>\nPLOS One, May 2018 &#8211; <a href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0196815\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication <\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/04\/Poster-AACR-2018-PCPV.pdf\" title=\"Pseudocowpox: A next generation viral vector for cancer immunotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox: A next generation viral vector for cancer immunotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Karolina Rittner, et al.<br \/>\nAACR 2018, April 2018 &#8211; Abstract available on the <a href=\"http:\/\/www.abstractsonline.com\/pp8\/#!\/4562\/presentation\/10603\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>AACR 2018 website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/04\/Poster-AACR-2018-PCPV.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma<\/div> <div class=\"lcp_content\"><p>Johann Foloppe, et al.<br \/>\nInternational Oncolytic Virus Conference, April 2018<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/04\/International_Oncolytic_Virus_Conference_2018_Oxford-TG6002.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B<\/div> <div class=\"lcp_content\"><p>Martin F. Sprinzl, et al.<br \/>\nAASLD &amp; Hepatology, October 2017<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2017\/10\/Poster-AASLD-2017-TG1050.02.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-017-0274-x\" title=\"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC<\/div> <\/a><div class=\"lcp_content\"><p>Caroline Tosch, et al.<br \/>\nJournal for ImmunoTherapy of Cancer, 2017, 5:70 &#8211; <a href=\"https:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-017-0274-x\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2017.1373921\" title=\"Sequential administration of MVA-based vaccines and PD-1\/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-\u03b2Gal and MVA-MUC1 (TG4010) in a murine tumor model\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Sequential administration of MVA-based vaccines and PD-1\/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-\u03b2Gal and MVA-MUC1 (TG4010) in a murine tumor model<\/div> <\/a><div class=\"lcp_content\"><p>Christelle Remy-Ziller, et al.<br \/>\nHuman Vaccines &amp; Immunotherapeutics, 2017, 19:0 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2017.1373921\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/search\/2mKQ\" title=\"A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\"><p>Maud Toulmonde, et al.<br \/>\nESMO 2017, September 11, 2017, 13:15 &#8211; 14:15, Hall 8<br \/>\nDownload the poster <a href=\"https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/search\/2mKQ\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-\u03b1 Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy<\/div> <div class=\"lcp_content\"><p>Laetitia Fend, et al.<br \/>\nCancer Research, July 2017, DOI: 10.1158\/0008-5472.CAN-16-2165 \u2013 <a href=\"http:\/\/cancerres.aacrjournals.org\/content\/early\/2017\/07\/19\/0008-5472.CAN-16-2165\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2017\/04\/In-Situ-Biomarker-analysis-in-cancer-Immunotherapy-POSTER-.pdf\" title=\"In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC<\/div> <\/a><div class=\"lcp_content\"><p>Sandrine Cochin, et al.<br \/>\nCLARA, Forum de la recherche en canc\u00e9rologie, April 2017<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2017\/04\/In-Situ-Biomarker-analysis-in-cancer-Immunotherapy-POSTER-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade<\/div> <div class=\"lcp_content\"><p>Laetitia Fend, et al.<br \/>\nAACR, American Association for cancer Research, April 2017<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2017\/04\/4563-Poster-AACR-2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-016-0204-3\" title=\"Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen<\/div> <\/a><div class=\"lcp_content\"><p>Gilda G. Hillman, et al.<br \/>\nJournal for ImmunoTherapy of Cancer, January 2017 \u2013 <a href=\"http:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-016-0204-3\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/11\/AASLD-2016-poster-1868-Transgene.pdf\" title=\"TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.<\/div> <\/a><div class=\"lcp_content\"><p>Roland Kratzer, et al.<br \/>\nAASLD &amp; Hepatology, October 2016 &#8211; DOI: 10.1002\/hep.28800<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/11\/AASLD-2016-poster-1868-Transgene.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Patricia Kleinpeter, et al.<br \/>OncoImmunology, October 2016 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2016.1220467\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Patricia Kleinpeter, et al.<br \/>OncoImmunology, October 2016 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2016.1220467\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities<\/div> <div class=\"lcp_content\">\n<p><br \/>Johann Foloppe, et al.<br \/>10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada &#8211; 1-4 October 2016<br \/>Download the poster <a href=\"..\/..\/wp-content\/uploads\/2016\/10\/161005-Poster_Vancouver_VACV-intrabody.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene \u2013 HTS facility IGBMC, Illkirch \u2013 France IREBS, Illkirch, France \u2013 ICube, Strasbourg, France<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_RCN_FCU1.pdf\" title=\"Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene<\/div> <\/a><div class=\"lcp_content\"><p>Marine Ricordel, et al.<br \/>\nXXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_RCN_FCU1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_MVA_autophagy_inhib.pdf\" title=\"Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor<\/div> <\/a><div class=\"lcp_content\"><p>Anita Spindler, et al.<br \/>\nXXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_MVA_autophagy_inhib.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>Johann Foloppe, et al.<br>XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br>Download the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_TG6002.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/meetinglibrary.asco.org\/content\/122703?media=vm&amp;intcmp=AM15iPlanner-W eb-ViewPoster-122703\" title=\"A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF \/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF \/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy<\/div> <\/a><div class=\"lcp_content\"><p>Ghassan K. Abou-Alfa, et al.<br \/>\nASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois<br \/>\nDownload the poster <a href=\"http:\/\/meetinglibrary.asco.org\/content\/122703?media=vm&amp;intcmp=AM15iPlanner-W eb-ViewPoster-122703\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Jean Baptiste Marchand, et al.<br \/>XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>Download the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_OVV_AB_FaB_ScFv.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/04\/1604-Poster-AACR-format-122-244-v2.pdf\" title=\"Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition<\/div> <\/a><div class=\"lcp_content\"><p>Jean Baptiste Marchand, et al.<br \/>\nAACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/04\/1604-Poster-AACR-format-122-244-v2.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation <\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(15)00483-0\/abstract\" title=\"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nThe Lancet Oncology, December 2015, 17: 212\u201323 \u2013 <a href=\"http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(15)00483-0\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0143552\" title=\"A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates<\/div> <\/a><div class=\"lcp_content\"><p>Stephane Leung-Theung-Long, et al<br \/>\nPLOS One, November 24, 2015 DOI: 10.1371\/journal.pone.0143552 \u2013 <a href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0143552\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2015\/11\/SITC-2015-TG4010-TIME-Trial.pdf\" title=\"TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial<\/div> <\/a><div class=\"lcp_content\"><p>John Nemunaitis, et al.<br \/>\nSITC 2015, November 2015 \u2013 Abstract available on the <a href=\"http:\/\/www.immunotherapyofcancer.org\/supplements\/3\/S2\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2015\/11\/SITC-2015-TG4010-TIME-Trial.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26209840\" title=\"Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.<\/div> <\/a><div class=\"lcp_content\"><p>Ophelie Godon, et al.<br \/>\nVaccine. 2015 Aug 26;33(36):4548-53 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26209840\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/library.iaslc.org\/search?search_keyword=TG4010\" title=\"TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\n16th World Conference on Lung Cancer. September 2015, Denver, Colorado<br \/>\nDownload the poster <a href=\"http:\/\/library.iaslc.org\/search?search_keyword=TG4010\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2015\/05\/Poster-ASCO-2015_TG4010-TIME-Ph-2b-trial.pdf\" title=\"Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nASCO Annual Meeting 2015 &#8211; May 29-June 2, 2015 &#8211; Chicago, Illinois<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2015\/05\/Poster-ASCO-2015_TG4010-TIME-Ph-2b-trial.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation <\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(15)30039-8\/abstract\" title=\"TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models<\/div> <\/a><div class=\"lcp_content\"><p>Karine L\u00e9lu, et al.<br \/>\nJournal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 \u2013 <a href=\"http:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(15)30039-8\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2015\/04\/EASL2015-TG1050_presentation-PMartin_21042015.pdf\" title=\"TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models<\/div> <\/a><div class=\"lcp_content\"><p>Karine L\u00e9lu, et al.<br \/>\nEASL Liver Congress 2015, Vienna-23th April 2015<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2015\/04\/EASL2015-TG1050_presentation-PMartin_21042015.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2015\/04\/Poster-TG4010-AACR-2015-KR.pdf\" title=\"Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer<\/div> <\/a><div class=\"lcp_content\"><p>Karola Rittner, et al.<br \/>\nAACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2015\/04\/Poster-TG4010-AACR-2015-KR.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2015\/04\/Poster-MVA-VIRAL-PLATFORM-AACR-2015-JML.pdf\" title=\"The MVA viral platform for the treatment of cancer and chronic infectious diseases:  Clinical experience from four randomized controlled phase II studies\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>The MVA viral platform for the treatment of cancer and chronic infectious diseases:  Clinical experience from four randomized controlled phase II studies<\/div> <\/a><div class=\"lcp_content\"><p>Jean-Marc Limacher, et al.<br \/>\nAACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498.<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2015\/04\/Poster-MVA-VIRAL-PLATFORM-AACR-2015-JML.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.nature.com\/nrgastro\/journal\/vaop\/ncurrent\/full\/nrgastro.2015.8.html\" title=\"Viral hepatitis: HBV cure\u2014can we pin our hopes on immunotherapy ?\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral hepatitis: HBV cure\u2014can we pin our hopes on immunotherapy ?<\/div> <\/a><div class=\"lcp_content\"><p>Hung-Chih Yang, et al.<br \/>\nNature Reviews Gastroenterology &#038; Hepatology (2015) doi:10.1038\/nrgastro.2015.8 \u2013 <a href=\"http:\/\/www.nature.com\/nrgastro\/journal\/vaop\/ncurrent\/full\/nrgastro.2015.8.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=TG1050\" title=\"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.<\/div> <\/a><div class=\"lcp_content\"><p>Martin P, Dubois, et al.<br \/>\nGut. 2014 Nov 26, doi: 10.1136\/gutjnl-2014-308041 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=TG1050\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.immunotherapyofcancer.org\/content\/2\/S3\/O12\" title=\"TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nJournal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 \u2013 <a href=\"http:\/\/www.immunotherapyofcancer.org\/content\/2\/S3\/O12\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2014\/09\/ESMO-2014-Poster-TG4010-TIME-Ph-2b.pdf\" title=\"TIME: A Phase 2b\/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TIME: A Phase 2b\/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2014\/09\/ESMO-2014-Poster-TG4010-TIME-Ph-2b.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24726690\" title=\"Comparative analysis of immunization schedules using a novel adenovirus \u2013 based immunotherapeutic targeting hepatitis B in na\u00efve and tolerant mouse models.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Comparative analysis of immunization schedules using a novel adenovirus \u2013 based immunotherapeutic targeting hepatitis B in na\u00efve and tolerant mouse models.<\/div> <\/a><div class=\"lcp_content\"><p>Houda Boukhebza, et al.<br \/>\nVaccine. 2014, 32(26):3256-63. \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24726690\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/link.springer.com\/article\/10.1007%2Fs13665-014-0072-6\" title=\"Immunotherapy for non &#8211; small &#8211; cell lung cancer: current approaches.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immunotherapy for non &#8211; small &#8211; cell lung cancer: current approaches.<\/div> <\/a><div class=\"lcp_content\"><p>\nElisabeth Quoix, et al.<br \/>\nCurrent Respiratory Care Reports, 2014; 3 (1): 19-25 \u2013 <a href=\"http:\/\/link.springer.com\/article\/10.1007%2Fs13665-014-0072-6\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.immunotherapyofcancer.org\/content\/pdf\/2051-1426-1-S1-P90.pdf\" title=\"Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.<\/div> <\/a><div class=\"lcp_content\"><p>Mica\u00ebl De Meyer, et al.<br \/>\nJournal for Immunotherapy of Cancer, 2013 \u2013 <a href=\"http:\/\/www.immunotherapyofcancer.org\/content\/pdf\/2051-1426-1-S1-P90.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/onlinelibrary.wiley.com\/enhanced\/doi\/10.1002\/hep.26796\/#hep26796-sec-0009\" title=\"TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.<\/div> <\/a><div class=\"lcp_content\"><p>\nPerrine Martin, et al.<br \/>\nHepatology, 2013, (58) S1, 222A\u2013225A \u2013 <a href=\"http:\/\/onlinelibrary.wiley.com\/enhanced\/doi\/10.1002\/hep.26796\/#hep26796-sec-0009\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813603931\" title=\"Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.<\/div> <\/a><div class=\"lcp_content\"><p>Houda Boukhebza, et al.<br \/>\nJournal of Hepatology, 2013, (58), Supplement 1, S161 \u2013 <a href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813603931\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813601324\" title=\"130 \u2013 A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>130 \u2013 A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.<\/div> <\/a><div class=\"lcp_content\"><p>Perrine Martin, et al.<br \/>\nJournal of Hepatology, 2013, (58), Supplement 1, S57\u2013S58. \u2013 <a href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813601324\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/31\/15_suppl\/4122?sid=e16b8da1-8ce1-4b77-8ecd-372140abfe94\" title=\"Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)<\/div> <\/a><div class=\"lcp_content\"><p>J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn<br \/>\n<em>Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122)<\/em><br \/>\n<span style=\"display:block\">[Publication]<\/span><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/31\/15_suppl\/3608?sid=e16b8da1-8ce1-4b77-8ecd-372140abfe94\" title=\"Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)<\/div> <\/a><div class=\"lcp_content\"><p>J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, J. Lee, W.K. Kang, J.O. Park, A. Pelusio, C. Breitbach, D.H. Kirn<br \/>\n<em>Journal of clinical Oncology, 2013, 31, (suppl; abstr 3608)<\/em><br \/>\n<span style=\"display:block\">[Publication]<\/span><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23677592\" title=\"Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans<\/div> <\/a><div class=\"lcp_content\"><p>\nMi Kyung Kim, et al.<br \/>\nScience Translational Medicine. 2013 May 15;5(185):185ra63 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23677592\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Randomized+dose-finding+clinical+trial+of+oncolytic\" title=\"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer<\/div> <\/a><div class=\"lcp_content\"><p>Jeong Heo, et al.<br \/>\nNature Medicine, 2013 (3):329-36. doi: 10.1038\/nm.3089. Epub 2013 Feb 10. \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Randomized+dose-finding+clinical+trial+of+oncolytic\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23496666\" title=\"Therapeutic cancer vaccines in the treatment of non-small cell lung cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Therapeutic cancer vaccines in the treatment of non-small cell lung cancer<\/div> <\/a><div class=\"lcp_content\"><p>\nJean-Marc Limacher, et al.<br \/>\nExpert Review of Vaccines, 2013; 12(3): 263-270 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23496666\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-5 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab5\" id=\"CP-produit\">\n<p class=\"eplus-wrapper wp-block-paragraph\">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.<\/p>\n<\/div>\n<\/div><\/div>\n\n\n\n<h2>\u00a0<\/h2>\n<h2 class=\"cgDeg\" style=\"color: var(--tgo3);\">Classement par date\u00a0<\/h2>\n<p>\u00a0<\/p>\n\n\n\n<div class=\"wp-block-uagb-tabs uagb-block-211bb0b6 uagb-tabs__wrap uagb-tabs__hstyle3-desktop uagb-tabs__hstyle3-tablet uagb-tabs__stack1-mobile uagb-tabs__vstyle6-mobile\" data-tab-active=\"0\" id=\"CP-date\"><ul class=\"uagb-tabs__panel uagb-tabs__align-left\" role=\"tablist\"><li class=\"uagb-tab uagb-tabs__active\" role=\"none\"><a href=\"#uagb-tabs__tab0\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"0\" role=\"tab\"><div>2026<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab1\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"1\" role=\"tab\"><div>2025<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab2\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"2\" role=\"tab\"><div>2024<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab3\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"3\" role=\"tab\"><div>2023<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab4\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"4\" role=\"tab\"><div>2022<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab5\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"5\" role=\"tab\"><div>2021<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab6\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"6\" role=\"tab\"><div>2020<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab7\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"7\" role=\"tab\"><div>2019<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab8\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"8\" role=\"tab\"><div>2018<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab9\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"9\" role=\"tab\"><div>2017<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab10\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"10\" role=\"tab\"><div>2016<\/div><\/a><\/li><li class=\"uagb-tab \" role=\"none\"><a href=\"#uagb-tabs__tab11\" class=\"uagb-tabs-list uagb-tabs__icon-position-left\" data-tab=\"11\" role=\"tab\"><div>All<\/div><\/a><\/li><\/ul><div class=\"uagb-tabs__body-wrap\">\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-0 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab0\" id=\"CP-date\">\n<p class=\"eplus-wrapper wp-block-paragraph\">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.<\/p>\n\n\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\" title=\"PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">J. Foloppe et al.\n<br>SITC 2026<br>\n&#8211; Abstract disponible sur le site du <a href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\"><strong>SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261103_SITC_Abstract.pdf\"><strong>Abstract<\/strong><\/a>&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261107_PosterSITC2026.pdf\"><strong>Poster<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\" title=\"Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Agaoua et al.\n<br>frontiers in Bioengineering and Biotechnology<br>\n&#8211; Article disponible sur le site de <a href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\"><strong>frontiers<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fbioe-14-1943548.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\" title=\"A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al. <br>Article disponible sur <a href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\"><strong>le site de Nature Communications<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/s41467-026-76667-1.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/isevjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jev2.70307\" title=\"Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">L. Walther, et al. <br>Article disponible sur <a href=\"https:\/\/isevjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jev2.70307\"><strong>le site de l&rsquo;ISEV<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260619_JEV_LWalther.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/infectiouscongress.com\/program\/scientific-program\/2026\/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl\" title=\"Robust Protection Against Monkeypox Virus Mediated by a Novel Cell\u2011Line\u2013Derived MVA Vaccine (TG-MVACL)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Robust Protection Against Monkeypox Virus Mediated by a Novel Cell\u2011Line\u2013Derived MVA Vaccine (TG-MVACL)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">N. Silvestre, et al. <br>World Congress on Infectious Diseases WCID 2026 Abstract disponible sur le <a href=\"https:\/\/infectiouscongress.com\/program\/scientific-program\/2026\/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl\"><strong>site du WCID<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Abstract_WCID_2026.pdf\"><strong>abstract <\/strong><\/a> &#8211; T\u00e9l\u00e9charger la<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2026_WCID_TGMVA.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_Abstract.pdf\" title=\"Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Agaoua et al.\n<br>International Oncolytic Virus Conference 2026<\/br>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_Abstract.pdf\"><strong>Abstract<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_SOVIV.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\" title=\"TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">K. Bidet-Huang\n<br>World Vaccine Congress 2026<\/br>\n&#8211; T\u00e9l\u00e9charger la <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" title=\"Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>medRxiv<\/br>\nPrepublication disponible sur le site <a href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" ><strong>medRxiv <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/medRxiv_TG4050.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-1 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab1\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3705\" title=\"Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">P. Erbs, et al.\n<br>Cancers 2025<\/br>\nAbstract disponible sur le site <a href=\"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3705\" ><strong>MDPI<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/McGuckin-et-al-Cancers-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" title=\"VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">B. Grellier, et al.\n<br>ESMO-AI 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" ><strong>site de l&rsquo;ESMO-AI<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250901_ESMO-AI_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMOAI2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" title=\"Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>SITC 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" ><strong> site du JITC <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/SITC2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251107_TG4050_SITC2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" title=\"Contribution de la levure \u00e0 la virologie synth\u00e9tique\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Contribution de la levure \u00e0 la virologie synth\u00e9tique<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Rey, et al.\n<br>Virologie 2025<\/br>\nArticle disponible sur le <a href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" ><strong>site de JLE<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Rey-contribution-of-yeast-to-synthetic-virology-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=955P\" title=\"Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Lebbe, et al.\n<br>ESMO 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=955P\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_Abstract_ESMO2025.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251018_BT001_ESMO2025.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=1592eP\" title=\"Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>ESMO 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=1592eP\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/MVA-Safety_ASCO-2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMO2025_SafetyMVA_ePoster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fmicb-16-1656984.pdf\" title=\"TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">J. Foloppe, et al.\n<br>Frontiers in Microbiology Septembre 2025<\/br>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fmicb-16-1656984.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250807_CICON2025_Poster.pdf\" title=\"A Pseudocowpox virus vector to generate human B cell-based vaccines\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Pseudocowpox virus vector to generate human B cell-based vaccines<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Thioudellet, et al.\n<br>CICON 2025<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250807_CICON2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Utilisation de l&rsquo;analyseur xCELLigence RTCA eSight pour l&rsquo;\u00e9valuation de la nouvelle platefrome de virus oncolytique de Transgene<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper\">B. Moreau et al.<br>AFH 2025<br>T\u00e9l\u00e9charger le poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AFH2025_BaM.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>ici<\/strong><\/a><br><em>Poster pr\u00e9sentation<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" title=\"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>ASCO 2025<\/br>\nAbstract disponible sur le  <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" ><strong>site de l&rsquo;ASCO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250522_TG4050_ASCO2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ASCO2025_TG4050.pdf\"><strong>Pr\u00e9sentation Orale Rapide<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT420440\" title=\"Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-na\u00efve recurrent and\/or metastatic(R\/M) HPV16-positive cervical or anogenital cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-na\u00efve recurrent and\/or metastatic(R\/M) HPV16-positive cervical or anogenital cancer<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>ASCO 2025<\/br>\nAbstract disponible sur le  <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT420440\" ><strong>site de l&rsquo;ASCO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250522_TG4001_ASCO2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ASCO2025_TG4001_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper\">E. J. West et al.<br>Clinical Cancer Research April 2025<br>Lire l&rsquo;article <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ccr-24-2498.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>ici<\/strong><\/a><br><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-2 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab2\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" title=\"Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.<\/p>\n<p>SITC 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" ><strong>site du SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/iovc2024.nl\/\" title=\"TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">J. Foloppe, et al.<\/p>\n<p>IOVC 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/iovc2024.nl\/\" ><strong>site de l&rsquo;IOVC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Abstract_IOVC_2024.pdf\"><strong>abstract <\/strong><\/a>et le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_IOVC_2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.cell.com\/molecular-therapy-family\/oncology\/fulltext\/S2950-3299(24)00129-2\" title=\"Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">U. Hirigoyen, et al.<\/p>\n<p>Oncology 2024<\/p>\n<p>Article disponible sur le  <a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/oncology\/fulltext\/S2950-3299(24)00129-2\" ><strong>site Molecular Therapy Oncology<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Hirigoyen-et-al-2024.pdf\"><strong>Article <\/strong><\/a>\n<\/p>\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal_2\/presentation\/list?q=1024P\" title=\"Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">S. Champiat, et al.<\/p>\n<p>ESMO 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal_2\/presentation\/list?q=1024P\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_ESMO2024-2.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_ESMO2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/static1.squarespace.com\/static\/56dee71e555986fb3ae583e2\/t\/66db4e7cb9451f7aac7fcd10\/1725648512282\/CICON24+Abstracts+FINAL+090524+v4.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">L.Fend, et al.<\/p>\n<p>ESMO 2024&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/static1.squarespace.com\/static\/56dee71e555986fb3ae583e2\/t\/66db4e7cb9451f7aac7fcd10\/1725648512282\/CICON24+Abstracts+FINAL+090524+v4.pdf\" ><strong>CICON website<\/strong><\/a>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/CICON2024_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/CICON2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/jitc\/12\/7\/e009302.full.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">F. Azar et al.\n<br>Journal for ImmunoTherapy of Cancer July 2024<\/br>\nArticle disponible sur le <a href=\"https:\/\/jitc.bmj.com\/content\/jitc\/12\/7\/e009302.full.pdf\" ><strong>site du JITC<\/strong><\/a>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" title=\"Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Lalanne, et al.<\/p>\n<p>AACR 2024&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" ><strong>AACR website<\/strong><\/a>\n&#8211; Download the <a href=\"\nhttps:\/\/www.transgene.com\/wp-content\/uploads\/20240209_AACR2024_TG4050_poster.pdf\"><strong>poster <\/strong><\/a><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-3 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab3\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804923003337\" title=\"Phase Ib\/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\"> C. Le Tourneau, et al.<br\/>European Journal of Cancer, July 2023 (191)<br\/>T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804923003337\"><strong>Article<\/strong><\/a><br\/><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" title=\"Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.<\/p>\n<p>ASCO 2023&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" ><strong>ASCO website<\/strong><\/a>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230525_TG4050_ASCO_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_ASCO2023_Safety_Immunogenicity_TG4050.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">H. Le et al.<br>AACR 2023<br>Download the poster <a rel=\"noreferrer noopener\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_PatientDerivedLungTumoroid_poster.pdf\" target=\"_blank\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>PoxSTG, a novel chimeric poxvirus with improved oncolytic potency<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">P. Erbs et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Novel_Chimeric_Poxvirus_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">A. Lalane et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Immunogenicity_Activity_TG4050_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2023_TG4001_Poster.pdf\" title=\"A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>AACR 2023<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2023_TG4001_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/TG6002-poster-AACR-2023.pdf\" title=\"TG6002 oncolytic vaccinia virus and chemotherapy synergy: apromising strategy for pancreatic ductal adenocarcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002 oncolytic vaccinia virus and chemotherapy synergy: apromising strategy for pancreatic ductal adenocarcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Samson, et al.\n<br>AACR 2023<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/TG6002-poster-AACR-2023.pdf\"><strong>Poster<\/strong><\/a>\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">JM. Marchand et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Vectorized_Anti-PD1_sdAb_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_TG6050_TME_remodeling_poster.pdf\" title=\"TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">JB. Marchand et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_TG6050_TME_remodeling_poster.pdf\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">L. Walther et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_ExtracellularVesicles_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\">\n<p><br \/>Christophe Le Tourneau et al.<br \/>ESMO 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-4 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab4\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)<\/div> <div class=\"lcp_content\">\n<p>JP Delord, et al.<br \/>ASCO 2022 <br \/>Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong> <\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_NEC_TG4050_ASCO2022_poster.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong> <\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination<\/div> <div class=\"lcp_content\"><p>Rodrigo Nalio Ramos, et al.<br \/>\nClinical &amp; Translational Immunology, May 8 2022 &#8211; <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cti2.1392\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMO2022_TG6002_Poster.pdf\" title=\"Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">V. Moreno, et al.\n<br>ESMO 2022<\/br>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMO2022_TG6002_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/16993\" title=\"Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">JB Marchand et al.<\/p>\n<p>AACR 2022<\/p>\n<p>Abstract disponible sur le site de l&rsquo;<a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/16993\" ><strong>AACR<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2022_BT001_Poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients<\/div> <div class=\"lcp_content\">\n<p>MS Block et al.<br \/>AACR 2022<br \/>Read the abstract <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/20200\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_TG4050_AACR2022_poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorized Treg-depleting \u03b1CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject \u00ab\u00a0cold\u00a0\u00bb tumors<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">Semmrich M, Marchand J, Fend L, et al<\/p>\n<p>Journal for ImmunoTherapy of Cancer 2022<\/p>\n<p>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/jitc.bmj.com\/content\/10\/1\/e003488\" target=\"_blank\" rel=\"noopener\"><strong>article<\/strong><\/a><br><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-5 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab5\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene-Poster-TG6002-ESMO-2021.pdf\" title=\"Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas<\/div> <\/a><div class=\"lcp_content\"><p class=\"eplus-emXPV0 eplus-wrapper\">P. Cassier et al.<br \/>\nESMO 2021<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene-Poster-TG6002-ESMO-2021.pdf\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-Euroocs-hle-2021-version-finale.pdf\" title=\"3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses<\/div> <\/a><div class=\"lcp_content\"><p><br \/>H\u00e9l\u00e8ne L\u00ea et al.<br \/>EUROoCS 2021<br \/>Download the Poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-Euroocs-hle-2021-version-finale.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas<\/div> <div class=\"lcp_content\"><p>K. Bendjama et al.<br \/>\nAACR 2021<br \/>\nRead the abstract <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/9325\/presentation\/4663\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/TG6002-_AACR_2021_poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33798643\/\" title=\"Immunocompetent cancer-on-chip models to assess immuno-oncology therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immunocompetent cancer-on-chip models to assess immuno-oncology therapy<\/div> <\/a><div class=\"lcp_content\"><p>Tengku Ibrahim Maulana, et al.<br \/>\nAdv Drug Deliv Rev., March 30 2021 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33798643\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs<\/div> <div class=\"lcp_content\"><p>Franck Gallardo, et al.<br \/>\nBiomedicines, November 26 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33256205\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC<\/div> <div class=\"lcp_content\"><p>Adrian von Witzleben, et al.<br \/>\nFront Oncol., January 26 2021 &#8211; <a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.591063\/full\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-6 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab6\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>Franck Gallardo, et al.<br>Biomedicines, November 26 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33256205\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>J\u00e9r\u00e9my B\u00e9guin, et al.<br>Molecular Therapy Oncolytics, September 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33072863\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>J\u00e9r\u00e9my B\u00e9guin, et al.<br>Molecular Therapy Oncolytics, September 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33072863\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p>Jean-Baptiste Marchand et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer<\/div> <div class=\"lcp_content\">\n<p><br \/>J\u00e9r\u00e9my B\u00e9guin, et al.<br \/>Molecular Therapy Oncolytics, September 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33072863\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs<\/div> <div class=\"lcp_content\">\n<p><br \/>J\u00e9r\u00e9my B\u00e9guin, et al.<br \/>BMC Vet Res., August 25 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32843040\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" title=\"Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine<\/div> <\/a><div class=\"lcp_content\"><p>H. Le et al.<br \/>\nEUROoCS 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-6010.pdf\" title=\"Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects<\/div> <\/a><div class=\"lcp_content\"><p>J. Foloppe et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-6010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p><br \/>Jean-Baptiste Marchand et al.<br \/>AACR 2020<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" title=\"Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine<\/div> <\/a><div class=\"lcp_content\"><p>B. Mallone et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_Transgene_BT-001_Immuno_Onco_2020.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p>Marchand, Semmrich, Fend et al.<br \/>\nImmuno-Oncology summit<br \/>\nDownload the poster<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_Transgene_BT-001_Immuno_Onco_2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-7 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab7\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Poster-0710-AASLD-2019-TG1050-T101_Metaanalyse.pdf\" title=\"Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe\/Canada or China\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe\/Canada or China<\/div> <\/a><div class=\"lcp_content\">\n<p><br \/>Fabien Zoulim et al.<br \/>AASLD 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Poster-0710-AASLD-2019-TG1050-T101_Metaanalyse.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Transgene-SITC-2019-Poster.pdf\" title=\"Oncolytic Vaccinia virus contains a potent CD80\/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic Vaccinia virus contains a potent CD80\/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\"><br>Jean-Baptiste Marchand et al.<br>SITC 2019<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Transgene-SITC-2019-Poster.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\"><p>Christophe Le Tourneau et al.<br \/>\nESMO 2019<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\">\n<p><br \/>Christophe Le Tourneau et al.<br \/>ESMO 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up<\/div> <div class=\"lcp_content\"><p>Diane. M. Harper, et al.<br \/>Gynecologic Oncology, April 2019 &#8211; <a href=\"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.250\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>The publication has been featured in <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30224-4\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>The Lancet Oncology<\/strong><\/a> and <a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/cervicalcancer\/79117\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Medpage Today<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up<\/div> <div class=\"lcp_content\">\n<p><br \/>Diane M. Harper, et al.<br \/>Gynecologic Oncology, April 2019 &#8211; <a href=\"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.250\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>The publication has been featured in <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30224-4\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>The Lancet Oncology<\/strong><\/a> and <a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/cervicalcancer\/79117\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Medpage Today<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism<\/div> <div class=\"lcp_content\"><p><br \/>Johann Foloppe, et al.<br \/>Molecular Therapy Oncolytics, March 2019 &#8211; <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6461584\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-8 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab8\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/11\/Poster_AASLD-2018_TG1050_COMBO_FINAL_30OCT18.pdf\" title=\"Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice<\/div> <\/a><div class=\"lcp_content\"><p>Roland Kratzer, et al.<br \/>\nAASLD, The Liver Meeting 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.30257\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>AASLD website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster_AASLD-2018_TG1050_COMBO_FINAL_30OCT18.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene &#8211; Laboratoire de Recherches Biochirurgicales, Universit\u00e9 Paris Descartes, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France &#8211; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France &#8211; H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France &#8211; Alnylam Pharmaceuticals, Cambridge, USA &#8211; The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan, China<\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment<\/div> <div class=\"lcp_content\"><p>Jean-Baptiste Marchand et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/11\/SITC-2018-Poster-Invir.IO_.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene \u2013 BioInvent International A.B, Sweden<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/11\/Poster-AASLD-2018-TG1050.02.pdf\" title=\"Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study<\/div> <\/a><div class=\"lcp_content\"><p>Claire Fournier, et al.<br \/>\nAASLD, The Liver Meeting 2018, November 2018 &#8211; Abstract available on the <strong><a href=\"https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.30257\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>AASLD website<\/strong><\/a><\/strong><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/11\/Poster-AASLD-2018-TG1050.02.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-myvac.pdf\" title=\"myvac\u2122 Viral based vaccine for personalized neoantigen-directed cancer therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>myvac\u2122 Viral based vaccine for personalized neoantigen-directed cancer therapy<\/div> <\/a><div class=\"lcp_content\"><p>Christian Ottensmeier, et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-myvac.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/a><\/p>\n<p>Collaboration between Transgene \u2013 University of Southampton, United Kingdom \u2013 La Jolla Institute for allergy and immunology, USA \u2013 University of Copenhagen, Denmark<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-PCPV.pdf\" title=\"Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Karola Rittner, et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-PCPV.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/TG_ASCO-Pexa-vec-poster-23-05-18-vf.pdf\" title=\"Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity<\/div> <\/a><div class=\"lcp_content\"><p>Alan Anthoney, et al.<br \/>\nASCO 2018, June 2018 &#8211; Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/TG_ASCO-Pexa-vec-poster-23-05-18-vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0196815\" title=\"A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis<\/div> <\/a><div class=\"lcp_content\"><p>Stephane Leung-Theung-Long, et al.<br \/>\nPLOS One, May 2018 &#8211; <a href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0196815\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication <\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/04\/Poster-AACR-2018-PCPV.pdf\" title=\"Pseudocowpox: A next generation viral vector for cancer immunotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox: A next generation viral vector for cancer immunotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Karolina Rittner, et al.<br \/>\nAACR 2018, April 2018 &#8211; Abstract available on the <a href=\"http:\/\/www.abstractsonline.com\/pp8\/#!\/4562\/presentation\/10603\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>AACR 2018 website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/04\/Poster-AACR-2018-PCPV.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma<\/div> <div class=\"lcp_content\"><p>Johann Foloppe, et al.<br \/>\nInternational Oncolytic Virus Conference, April 2018<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/04\/International_Oncolytic_Virus_Conference_2018_Oxford-TG6002.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-9 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab9\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B<\/div> <div class=\"lcp_content\"><p>Martin F. Sprinzl, et al.<br \/>\nAASLD &amp; Hepatology, October 2017<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2017\/10\/Poster-AASLD-2017-TG1050.02.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-017-0274-x\" title=\"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC<\/div> <\/a><div class=\"lcp_content\"><p>Caroline Tosch, et al.<br \/>\nJournal for ImmunoTherapy of Cancer, 2017, 5:70 &#8211; <a href=\"https:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-017-0274-x\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2017.1373921\" title=\"Sequential administration of MVA-based vaccines and PD-1\/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-\u03b2Gal and MVA-MUC1 (TG4010) in a murine tumor model\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Sequential administration of MVA-based vaccines and PD-1\/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-\u03b2Gal and MVA-MUC1 (TG4010) in a murine tumor model<\/div> <\/a><div class=\"lcp_content\"><p>Christelle Remy-Ziller, et al.<br \/>\nHuman Vaccines &amp; Immunotherapeutics, 2017, 19:0 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2017.1373921\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/search\/2mKQ\" title=\"A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\"><p>Maud Toulmonde, et al.<br \/>\nESMO 2017, September 11, 2017, 13:15 &#8211; 14:15, Hall 8<br \/>\nDownload the poster <a href=\"https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/search\/2mKQ\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" title=\"Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer<\/div> <\/a><div class=\"lcp_content\"><p>K. Bendjama, E. Qu\u00e9m\u00e9neur<br \/>\nHuman Vaccines and Immunotherapeutics, August 2017 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-\u03b1 Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy<\/div> <div class=\"lcp_content\"><p>Laetitia Fend, et al.<br \/>\nCancer Research, July 2017, DOI: 10.1158\/0008-5472.CAN-16-2165 \u2013 <a href=\"http:\/\/cancerres.aacrjournals.org\/content\/early\/2017\/07\/19\/0008-5472.CAN-16-2165\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma<\/div> <div class=\"lcp_content\"><p>Ahmed Idbaih, et al.<br \/>\nASCO 2017, June 2017 \u2013 <a href=\"https:\/\/meetinglibrary.asco.org\/record\/152427\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the abstract<\/strong><\/a><br \/>\n<em>Abstract<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2017\/04\/In-Situ-Biomarker-analysis-in-cancer-Immunotherapy-POSTER-.pdf\" title=\"In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC<\/div> <\/a><div class=\"lcp_content\"><p>Sandrine Cochin, et al.<br \/>\nCLARA, Forum de la recherche en canc\u00e9rologie, April 2017<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2017\/04\/In-Situ-Biomarker-analysis-in-cancer-Immunotherapy-POSTER-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade<\/div> <div class=\"lcp_content\"><p>Laetitia Fend, et al.<br \/>\nAACR, American Association for cancer Research, April 2017<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2017\/04\/4563-Poster-AACR-2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine<\/div> <div class=\"lcp_content\">\n<p><br \/>Faleh Husseini, et al.<br \/>Annals of Oncology, February 2017, DOI: https:\/\/doi.org\/10.1093\/annonc\/mdw440 \u2013 <a href=\"https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mdw440\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<p>TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.<\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-016-0204-3\" title=\"Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen<\/div> <\/a><div class=\"lcp_content\"><p>Gilda G. Hillman, et al.<br \/>\nJournal for ImmunoTherapy of Cancer, January 2017 \u2013 <a href=\"http:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-016-0204-3\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Patricia Kleinpeter, et al.<br \/>OncoImmunology, October 2016 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2016.1220467\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities<\/div> <div class=\"lcp_content\">\n<p><br \/>Johann Foloppe, et al.<br \/>10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada &#8211; 1-4 October 2016<br \/>Download the poster <a href=\"..\/..\/wp-content\/uploads\/2016\/10\/161005-Poster_Vancouver_VACV-intrabody.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene \u2013 HTS facility IGBMC, Illkirch \u2013 France IREBS, Illkirch, France \u2013 ICube, Strasbourg, France<\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-10 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab10\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/11\/AASLD-2016-poster-1868-Transgene.pdf\" title=\"TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.<\/div> <\/a><div class=\"lcp_content\"><p>Roland Kratzer, et al.<br \/>\nAASLD &amp; Hepatology, October 2016 &#8211; DOI: 10.1002\/hep.28800<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/11\/AASLD-2016-poster-1868-Transgene.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Patricia Kleinpeter, et al.<br \/>OncoImmunology, October 2016 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2016.1220467\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_RCN_FCU1.pdf\" title=\"Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene<\/div> <\/a><div class=\"lcp_content\"><p>Marine Ricordel, et al.<br \/>\nXXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_RCN_FCU1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_MVA_autophagy_inhib.pdf\" title=\"Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor<\/div> <\/a><div class=\"lcp_content\"><p>Anita Spindler, et al.<br \/>\nXXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_MVA_autophagy_inhib.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>Johann Foloppe, et al.<br>XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br>Download the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_TG6002.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/meetinglibrary.asco.org\/content\/122703?media=vm&amp;intcmp=AM15iPlanner-W eb-ViewPoster-122703\" title=\"A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF \/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF \/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy<\/div> <\/a><div class=\"lcp_content\"><p>Ghassan K. Abou-Alfa, et al.<br \/>\nASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois<br \/>\nDownload the poster <a href=\"http:\/\/meetinglibrary.asco.org\/content\/122703?media=vm&amp;intcmp=AM15iPlanner-W eb-ViewPoster-122703\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Jean Baptiste Marchand, et al.<br \/>XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>Download the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_OVV_AB_FaB_ScFv.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/04\/1604-Poster-AACR-format-122-244-v2.pdf\" title=\"Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition<\/div> <\/a><div class=\"lcp_content\"><p>Jean Baptiste Marchand, et al.<br \/>\nAACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/04\/1604-Poster-AACR-format-122-244-v2.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation <\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-uagb-tabs-child uagb-tabs__body-container uagb-inner-tab-11 uagb-tabs__vstyle6-mobile\" aria-labelledby=\"uagb-tabs__tab11\" id=\"CP-date\"><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/><ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\" title=\"PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>PoxSTG-EEV: a Novel Enveloped Virion\u2009\u2013\u2009Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">J. Foloppe et al.\n<br>SITC 2026<br>\n&#8211; Abstract disponible sur le site du <a href=\"https:\/\/jitc.bmj.com\/content\/14\/Suppl_2\/A1203\"><strong>SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261103_SITC_Abstract.pdf\"><strong>Abstract<\/strong><\/a>&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261107_PosterSITC2026.pdf\"><strong>Poster<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\" title=\"Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Agaoua et al.\n<br>frontiers in Bioengineering and Biotechnology<br>\n&#8211; Article disponible sur le site de <a href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2026.1943548\/full\"><strong>frontiers<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fbioe-14-1943548.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\" title=\"A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al. <br>Article disponible sur <a href=\"https:\/\/www.nature.com\/articles\/s41467-026-76667-1\"><strong>le site de Nature Communications<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/s41467-026-76667-1.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/isevjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jev2.70307\" title=\"Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">L. Walther, et al. <br>Article disponible sur <a href=\"https:\/\/isevjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jev2.70307\"><strong>le site de l&rsquo;ISEV<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260619_JEV_LWalther.pdf\"><strong>Article<\/strong><\/a><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/infectiouscongress.com\/program\/scientific-program\/2026\/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl\" title=\"Robust Protection Against Monkeypox Virus Mediated by a Novel Cell\u2011Line\u2013Derived MVA Vaccine (TG-MVACL)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Robust Protection Against Monkeypox Virus Mediated by a Novel Cell\u2011Line\u2013Derived MVA Vaccine (TG-MVACL)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">N. Silvestre, et al. <br>World Congress on Infectious Diseases WCID 2026 Abstract disponible sur le <a href=\"https:\/\/infectiouscongress.com\/program\/scientific-program\/2026\/robust-protection-against-monkeypox-virus-mediated-by-a-novel-cell-line-derived-mva-vaccine-tg-mvacl\"><strong>site du WCID<\/strong><\/a> &#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Abstract_WCID_2026.pdf\"><strong>abstract <\/strong><\/a> &#8211; T\u00e9l\u00e9charger la<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2026_WCID_TGMVA.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_Abstract.pdf\" title=\"Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Agaoua et al.\n<br>International Oncolytic Virus Conference 2026<\/br>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_Abstract.pdf\"><strong>Abstract<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260426_IOVC_SOVIV.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\" title=\"TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">K. Bidet-Huang\n<br>World Vaccine Congress 2026<\/br>\n&#8211; T\u00e9l\u00e9charger la <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20260401-WVC_Presentation.pdf\"><strong>pr\u00e9sentation orale<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" title=\"Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral-based individualized neoantigen vaccine as adjuvant treatment in resected 2 head and neck squamous cell carcinoma: immunogenicity and efficacy from a 3 randomized Phase I trial<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>medRxiv<\/br>\nPrepublication disponible sur le site <a href=\"https:\/\/www.medrxiv.org\/content\/10.64898\/2026.01.06.25342687v1\" ><strong>medRxiv <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/medRxiv_TG4050.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3705\" title=\"Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">P. Erbs, et al.\n<br>Cancers 2025<\/br>\nAbstract disponible sur le site <a href=\"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3705\" ><strong>MDPI<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/McGuckin-et-al-Cancers-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" title=\"VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>VacDesignR\u00ae: a Tool for Optimizing Recombinant Poxvirus Vaccine Production<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">B. Grellier, et al.\n<br>ESMO-AI 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/coasis_21451\/attendee\/confcal\/session\/list?q=Vacdesignr\" ><strong>site de l&rsquo;ESMO-AI<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250901_ESMO-AI_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMOAI2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" title=\"Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>SITC 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/jitc.bmj.com\/content\/13\/Suppl_2\/A569\" ><strong> site du JITC <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/SITC2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251107_TG4050_SITC2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" title=\"Contribution de la levure \u00e0 la virologie synth\u00e9tique\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Contribution de la levure \u00e0 la virologie synth\u00e9tique<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Rey, et al.\n<br>Virologie 2025<\/br>\nArticle disponible sur le <a href=\"https:\/\/www.jle.com\/fr\/revues\/vir\/e-docs\/contribution_de_la_levure_a_la_virologie_synthetique_354862\/article.phtml\" ><strong>site de JLE<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Rey-contribution-of-yeast-to-synthetic-virology-2025.pdf\"><strong>article <\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=955P\" title=\"Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Lebbe, et al.\n<br>ESMO 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=955P\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_Abstract_ESMO2025.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251018_BT001_ESMO2025.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=1592eP\" title=\"Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.\n<br>ESMO 2025<\/br>\nAbstract disponible sur le <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=1592eP\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/MVA-Safety_ASCO-2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMO2025_SafetyMVA_ePoster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fmicb-16-1656984.pdf\" title=\"TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">J. Foloppe, et al.\n<br>Frontiers in Microbiology Septembre 2025<\/br>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/fmicb-16-1656984.pdf\"><strong>Article<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250807_CICON2025_Poster.pdf\" title=\"A Pseudocowpox virus vector to generate human B cell-based vaccines\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Pseudocowpox virus vector to generate human B cell-based vaccines<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Thioudellet, et al.\n<br>CICON 2025<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250807_CICON2025_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Utilisation de l&rsquo;analyseur xCELLigence RTCA eSight pour l&rsquo;\u00e9valuation de la nouvelle platefrome de virus oncolytique de Transgene<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper\">B. Moreau et al.<br>AFH 2025<br>T\u00e9l\u00e9charger le poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AFH2025_BaM.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>ici<\/strong><\/a><br><em>Poster pr\u00e9sentation<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" title=\"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>ASCO 2025<\/br>\nAbstract disponible sur le  <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT495236\" ><strong>site de l&rsquo;ASCO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250522_TG4050_ASCO2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ASCO2025_TG4050.pdf\"><strong>Pr\u00e9sentation Orale Rapide<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT420440\" title=\"Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-na\u00efve recurrent and\/or metastatic(R\/M) HPV16-positive cervical or anogenital cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-na\u00efve recurrent and\/or metastatic(R\/M) HPV16-positive cervical or anogenital cancer<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>ASCO 2025<\/br>\nAbstract disponible sur le  <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT420440\" ><strong>site de l&rsquo;ASCO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250522_TG4001_ASCO2025_Abstract.pdf\"><strong>abstract <\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ASCO2025_TG4001_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper\">E. J. West et al.<br>Clinical Cancer Research April 2025<br>Lire l&rsquo;article <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ccr-24-2498.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>ici<\/strong><\/a><br><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" title=\"Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.<\/p>\n<p>SITC 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/www.sitcancer.org\/2024\/abstracts\/titles-and-publications?SITC%202024%20Abstract%20Titles%5Bquery%5D=650\" ><strong>site du SITC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/iovc2024.nl\/\" title=\"TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">J. Foloppe, et al.<\/p>\n<p>IOVC 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/iovc2024.nl\/\" ><strong>site de l&rsquo;IOVC<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Abstract_IOVC_2024.pdf\"><strong>abstract <\/strong><\/a>et le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_IOVC_2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.cell.com\/molecular-therapy-family\/oncology\/fulltext\/S2950-3299(24)00129-2\" title=\"Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">U. Hirigoyen, et al.<\/p>\n<p>Oncology 2024<\/p>\n<p>Article disponible sur le  <a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/oncology\/fulltext\/S2950-3299(24)00129-2\" ><strong>site Molecular Therapy Oncology<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Hirigoyen-et-al-2024.pdf\"><strong>Article <\/strong><\/a>\n<\/p>\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal_2\/presentation\/list?q=1024P\" title=\"Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">S. Champiat, et al.<\/p>\n<p>ESMO 2024&nbsp;<\/p>\n<p>Abstract disponible sur le  <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal_2\/presentation\/list?q=1024P\" ><strong>site de l&rsquo;ESMO<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_ESMO2024-2.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/BT001_ESMO2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/static1.squarespace.com\/static\/56dee71e555986fb3ae583e2\/t\/66db4e7cb9451f7aac7fcd10\/1725648512282\/CICON24+Abstracts+FINAL+090524+v4.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">L.Fend, et al.<\/p>\n<p>ESMO 2024&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/static1.squarespace.com\/static\/56dee71e555986fb3ae583e2\/t\/66db4e7cb9451f7aac7fcd10\/1725648512282\/CICON24+Abstracts+FINAL+090524+v4.pdf\" ><strong>CICON website<\/strong><\/a>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/CICON2024_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/CICON2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/jitc\/12\/7\/e009302.full.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-DVrMbh\">F. Azar et al.\n<br>Journal for ImmunoTherapy of Cancer July 2024<\/br>\nArticle disponible sur le <a href=\"https:\/\/jitc.bmj.com\/content\/jitc\/12\/7\/e009302.full.pdf\" ><strong>site du JITC<\/strong><\/a>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" title=\"Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Lalanne, et al.<\/p>\n<p>AACR 2024&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/10429\" ><strong>AACR website<\/strong><\/a>\n&#8211; Download the <a href=\"\nhttps:\/\/www.transgene.com\/wp-content\/uploads\/20240209_AACR2024_TG4050_poster.pdf\"><strong>poster <\/strong><\/a><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804923003337\" title=\"Phase Ib\/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\"> C. Le Tourneau, et al.<br\/>European Journal of Cancer, July 2023 (191)<br\/>T\u00e9l\u00e9charger l&rsquo; <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804923003337\"><strong>Article<\/strong><\/a><br\/><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" title=\"Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Ottensmeier, et al.<\/p>\n<p>ASCO 2023&nbsp;<\/p>\n<p>Abstract available on the <a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/218595\" ><strong>ASCO website<\/strong><\/a>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230525_TG4050_ASCO_Abstract.pdf\"><strong>abstract <\/strong><\/a>and the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_ASCO2023_Safety_Immunogenicity_TG4050.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">H. Le et al.<br>AACR 2023<br>Download the poster <a rel=\"noreferrer noopener\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_PatientDerivedLungTumoroid_poster.pdf\" target=\"_blank\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>PoxSTG, a novel chimeric poxvirus with improved oncolytic potency<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">P. Erbs et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Novel_Chimeric_Poxvirus_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">A. Lalane et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Immunogenicity_Activity_TG4050_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2023_TG4001_Poster.pdf\" title=\"A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">C. Le Tourneau, et al.\n<br>AACR 2023<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2023_TG4001_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/TG6002-poster-AACR-2023.pdf\" title=\"TG6002 oncolytic vaccinia virus and chemotherapy synergy: apromising strategy for pancreatic ductal adenocarcinoma\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002 oncolytic vaccinia virus and chemotherapy synergy: apromising strategy for pancreatic ductal adenocarcinoma<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">A. Samson, et al.\n<br>AACR 2023<\/br>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/TG6002-poster-AACR-2023.pdf\"><strong>Poster<\/strong><\/a>\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">JM. Marchand et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_Vectorized_Anti-PD1_sdAb_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_TG6050_TME_remodeling_poster.pdf\" title=\"TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">JB. Marchand et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_TG6050_TME_remodeling_poster.pdf\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\">L. Walther et al.<br>AACR 2023<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_ExtracellularVesicles_poster.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)<\/div> <div class=\"lcp_content\">\n<p>JP Delord, et al.<br \/>ASCO 2022 <br \/>Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong> <\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_NEC_TG4050_ASCO2022_poster.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong> <\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination<\/div> <div class=\"lcp_content\"><p>Rodrigo Nalio Ramos, et al.<br \/>\nClinical &amp; Translational Immunology, May 8 2022 &#8211; <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cti2.1392\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMO2022_TG6002_Poster.pdf\" title=\"Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">V. Moreno, et al.\n<br>ESMO 2022<\/br>\n&#8211; Download the <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/ESMO2022_TG6002_Poster.pdf\"><strong>Poster<\/strong><\/a>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/16993\" title=\"Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">JB Marchand et al.<\/p>\n<p>AACR 2022<\/p>\n<p>Abstract disponible sur le site de l&rsquo;<a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/16993\" ><strong>AACR<\/strong><\/a>\n&#8211; T\u00e9l\u00e9charger le <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/AACR2022_BT001_Poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>poster<\/strong><\/a><br><\/p>\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients<\/div> <div class=\"lcp_content\">\n<p>MS Block et al.<br \/>AACR 2022<br \/>Read the abstract <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/20200\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_TG4050_AACR2022_poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorized Treg-depleting \u03b1CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject \u00ab\u00a0cold\u00a0\u00bb tumors<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-DVrMbh\">Semmrich M, Marchand J, Fend L, et al<\/p>\n<p>Journal for ImmunoTherapy of Cancer 2022<\/p>\n<p>\n&#8211; T\u00e9l\u00e9charger l&rsquo;<a href=\"https:\/\/jitc.bmj.com\/content\/10\/1\/e003488\" target=\"_blank\" rel=\"noopener\"><strong>article<\/strong><\/a><br><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene-Poster-TG6002-ESMO-2021.pdf\" title=\"Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas<\/div> <\/a><div class=\"lcp_content\"><p class=\"eplus-emXPV0 eplus-wrapper\">P. Cassier et al.<br \/>\nESMO 2021<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene-Poster-TG6002-ESMO-2021.pdf\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-Euroocs-hle-2021-version-finale.pdf\" title=\"3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses<\/div> <\/a><div class=\"lcp_content\"><p><br \/>H\u00e9l\u00e8ne L\u00ea et al.<br \/>EUROoCS 2021<br \/>Download the Poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-Euroocs-hle-2021-version-finale.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas<\/div> <div class=\"lcp_content\"><p>K. Bendjama et al.<br \/>\nAACR 2021<br \/>\nRead the abstract <a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/9325\/presentation\/4663\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a> &#8211; Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/TG6002-_AACR_2021_poster.pdf\" target=\"_blank\" rel=\"noopener\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33798643\/\" title=\"Immunocompetent cancer-on-chip models to assess immuno-oncology therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immunocompetent cancer-on-chip models to assess immuno-oncology therapy<\/div> <\/a><div class=\"lcp_content\"><p>Tengku Ibrahim Maulana, et al.<br \/>\nAdv Drug Deliv Rev., March 30 2021 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33798643\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs<\/div> <div class=\"lcp_content\"><p>Franck Gallardo, et al.<br \/>\nBiomedicines, November 26 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33256205\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC<\/div> <div class=\"lcp_content\"><p>Adrian von Witzleben, et al.<br \/>\nFront Oncol., January 26 2021 &#8211; <a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.591063\/full\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>Franck Gallardo, et al.<br>Biomedicines, November 26 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33256205\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>J\u00e9r\u00e9my B\u00e9guin, et al.<br>Molecular Therapy Oncolytics, September 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33072863\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent\/metastatic (R\/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>J\u00e9r\u00e9my B\u00e9guin, et al.<br>Molecular Therapy Oncolytics, September 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33072863\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p>Jean-Baptiste Marchand et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer<\/div> <div class=\"lcp_content\">\n<p><br \/>J\u00e9r\u00e9my B\u00e9guin, et al.<br \/>Molecular Therapy Oncolytics, September 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33072863\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs<\/div> <div class=\"lcp_content\">\n<p><br \/>J\u00e9r\u00e9my B\u00e9guin, et al.<br \/>BMC Vet Res., August 25 2020 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32843040\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Read the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" title=\"Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine<\/div> <\/a><div class=\"lcp_content\"><p>H. Le et al.<br \/>\nEUROoCS 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" title=\"Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine<\/div> <\/a><div class=\"lcp_content\"><p>H. Le et al.<br \/>\nEUROoCS 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-6010.pdf\" title=\"Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects<\/div> <\/a><div class=\"lcp_content\"><p>J. Foloppe et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-6010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p><br \/>Jean-Baptiste Marchand et al.<br \/>AACR 2020<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" title=\"Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine<\/div> <\/a><div class=\"lcp_content\"><p>B. Mallone et al.<br \/>\nAACR 2020<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-myvac.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_Transgene_BT-001_Immuno_Onco_2020.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div> <\/a><div class=\"lcp_content\"><p>Marchand, Semmrich, Fend et al.<br \/>\nImmuno-Oncology summit<br \/>\nDownload the poster<a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_Transgene_BT-001_Immuno_Onco_2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Poster-0710-AASLD-2019-TG1050-T101_Metaanalyse.pdf\" title=\"Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe\/Canada or China\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe\/Canada or China<\/div> <\/a><div class=\"lcp_content\">\n<p><br \/>Fabien Zoulim et al.<br \/>AASLD 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Poster-0710-AASLD-2019-TG1050-T101_Metaanalyse.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Transgene-SITC-2019-Poster.pdf\" title=\"Oncolytic Vaccinia virus contains a potent CD80\/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic Vaccinia virus contains a potent CD80\/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming<\/div> <\/a><div class=\"lcp_content\">\n<p class=\"eplus-emXPV0 eplus-wrapper wp-block-paragraph\"><br>Jean-Baptiste Marchand et al.<br>SITC 2019<br>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/11\/Transgene-SITC-2019-Poster.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\"><p>Christophe Le Tourneau et al.<br \/>\nESMO 2019<br \/>\nDownload the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\">\n<p><br \/>Christophe Le Tourneau et al.<br \/>ESMO 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic HPV16 positive cancers<\/div> <div class=\"lcp_content\">\n<p><br \/>Christophe Le Tourneau et al.<br \/>ESMO 2019<br \/>Download the poster <a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/2019\/09\/TG4001.12_ESMO_2019_vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up<\/div> <div class=\"lcp_content\"><p>Diane. M. Harper, et al.<br \/>Gynecologic Oncology, April 2019 &#8211; <a href=\"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.250\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>The publication has been featured in <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30224-4\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>The Lancet Oncology<\/strong><\/a> and <a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/cervicalcancer\/79117\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Medpage Today<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up<\/div> <div class=\"lcp_content\">\n<p><br \/>Diane M. Harper, et al.<br \/>Gynecologic Oncology, April 2019 &#8211; <a href=\"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.250\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>The publication has been featured in <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30224-4\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>The Lancet Oncology<\/strong><\/a> and <a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/cervicalcancer\/79117\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Medpage Today<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n\n\n\n\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism<\/div> <div class=\"lcp_content\"><p><br \/>Johann Foloppe, et al.<br \/>Molecular Therapy Oncolytics, March 2019 &#8211; <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6461584\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/11\/Poster_AASLD-2018_TG1050_COMBO_FINAL_30OCT18.pdf\" title=\"Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice<\/div> <\/a><div class=\"lcp_content\"><p>Roland Kratzer, et al.<br \/>\nAASLD, The Liver Meeting 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.30257\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>AASLD website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster_AASLD-2018_TG1050_COMBO_FINAL_30OCT18.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene &#8211; Laboratoire de Recherches Biochirurgicales, Universit\u00e9 Paris Descartes, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France &#8211; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France &#8211; H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France &#8211; Alnylam Pharmaceuticals, Cambridge, USA &#8211; The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan, China<\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment<\/div> <div class=\"lcp_content\"><p>Jean-Baptiste Marchand et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/11\/SITC-2018-Poster-Invir.IO_.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene \u2013 BioInvent International A.B, Sweden<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/11\/Poster-AASLD-2018-TG1050.02.pdf\" title=\"Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study<\/div> <\/a><div class=\"lcp_content\"><p>Claire Fournier, et al.<br \/>\nAASLD, The Liver Meeting 2018, November 2018 &#8211; Abstract available on the <strong><a href=\"https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.30257\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>AASLD website<\/strong><\/a><\/strong><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/11\/Poster-AASLD-2018-TG1050.02.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-myvac.pdf\" title=\"myvac\u2122 Viral based vaccine for personalized neoantigen-directed cancer therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>myvac\u2122 Viral based vaccine for personalized neoantigen-directed cancer therapy<\/div> <\/a><div class=\"lcp_content\"><p>Christian Ottensmeier, et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-myvac.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/a><\/p>\n<p>Collaboration between Transgene \u2013 University of Southampton, United Kingdom \u2013 La Jolla Institute for allergy and immunology, USA \u2013 University of Copenhagen, Denmark<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-PCPV.pdf\" title=\"Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Karola Rittner, et al.<br \/>\nSITC 2018, November 2018 &#8211; Abstract available on the <a href=\"https:\/\/www.sitcancer.org\/2018\/abstracts\/general\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/Poster-SITC-2018-PCPV.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/..\/wp-content\/uploads\/2018\/11\/TG_ASCO-Pexa-vec-poster-23-05-18-vf.pdf\" title=\"Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity<\/div> <\/a><div class=\"lcp_content\"><p>Alan Anthoney, et al.<br \/>\nASCO 2018, June 2018 &#8211; Abstract available on the <a href=\"http:\/\/abstracts.asco.org\/214\/AbstView_214_214143.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>ASCO website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/..\/wp-content\/uploads\/2018\/11\/TG_ASCO-Pexa-vec-poster-23-05-18-vf.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0196815\" title=\"A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis<\/div> <\/a><div class=\"lcp_content\"><p>Stephane Leung-Theung-Long, et al.<br \/>\nPLOS One, May 2018 &#8211; <a href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0196815\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication <\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2018\/04\/Poster-AACR-2018-PCPV.pdf\" title=\"Pseudocowpox: A next generation viral vector for cancer immunotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pseudocowpox: A next generation viral vector for cancer immunotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Karolina Rittner, et al.<br \/>\nAACR 2018, April 2018 &#8211; Abstract available on the <a href=\"http:\/\/www.abstractsonline.com\/pp8\/#!\/4562\/presentation\/10603\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>AACR 2018 website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/04\/Poster-AACR-2018-PCPV.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma<\/div> <div class=\"lcp_content\"><p>Johann Foloppe, et al.<br \/>\nInternational Oncolytic Virus Conference, April 2018<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2018\/04\/International_Oncolytic_Virus_Conference_2018_Oxford-TG6002.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B<\/div> <div class=\"lcp_content\"><p>Martin F. Sprinzl, et al.<br \/>\nAASLD &amp; Hepatology, October 2017<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2017\/10\/Poster-AASLD-2017-TG1050.02.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-017-0274-x\" title=\"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC<\/div> <\/a><div class=\"lcp_content\"><p>Caroline Tosch, et al.<br \/>\nJournal for ImmunoTherapy of Cancer, 2017, 5:70 &#8211; <a href=\"https:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-017-0274-x\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2017.1373921\" title=\"Sequential administration of MVA-based vaccines and PD-1\/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-\u03b2Gal and MVA-MUC1 (TG4010) in a murine tumor model\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Sequential administration of MVA-based vaccines and PD-1\/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-\u03b2Gal and MVA-MUC1 (TG4010) in a murine tumor model<\/div> <\/a><div class=\"lcp_content\"><p>Christelle Remy-Ziller, et al.<br \/>\nHuman Vaccines &amp; Immunotherapeutics, 2017, 19:0 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2017.1373921\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/search\/2mKQ\" title=\"A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors<\/div> <\/a><div class=\"lcp_content\"><p>Maud Toulmonde, et al.<br \/>\nESMO 2017, September 11, 2017, 13:15 &#8211; 14:15, Hall 8<br \/>\nDownload the poster <a href=\"https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/search\/2mKQ\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" title=\"Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer<\/div> <\/a><div class=\"lcp_content\"><p>K. Bendjama, E. Qu\u00e9m\u00e9neur<br \/>\nHuman Vaccines and Immunotherapeutics, August 2017 &#8211; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28846477\/\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>Read the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-\u03b1 Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy<\/div> <div class=\"lcp_content\"><p>Laetitia Fend, et al.<br \/>\nCancer Research, July 2017, DOI: 10.1158\/0008-5472.CAN-16-2165 \u2013 <a href=\"http:\/\/cancerres.aacrjournals.org\/content\/early\/2017\/07\/19\/0008-5472.CAN-16-2165\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma<\/div> <div class=\"lcp_content\"><p>Ahmed Idbaih, et al.<br \/>\nASCO 2017, June 2017 \u2013 <a href=\"https:\/\/meetinglibrary.asco.org\/record\/152427\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the abstract<\/strong><\/a><br \/>\n<em>Abstract<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2017\/04\/In-Situ-Biomarker-analysis-in-cancer-Immunotherapy-POSTER-.pdf\" title=\"In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC<\/div> <\/a><div class=\"lcp_content\"><p>Sandrine Cochin, et al.<br \/>\nCLARA, Forum de la recherche en canc\u00e9rologie, April 2017<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2017\/04\/In-Situ-Biomarker-analysis-in-cancer-Immunotherapy-POSTER-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade<\/div> <div class=\"lcp_content\"><p>Laetitia Fend, et al.<br \/>\nAACR, American Association for cancer Research, April 2017<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2017\/04\/4563-Poster-AACR-2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine<\/div> <div class=\"lcp_content\">\n<p><br \/>Faleh Husseini, et al.<br \/>Annals of Oncology, February 2017, DOI: https:\/\/doi.org\/10.1093\/annonc\/mdw440 \u2013 <a href=\"https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mdw440\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<p>TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.<\/p>\n\n\n\n\n\n\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-016-0204-3\" title=\"Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen<\/div> <\/a><div class=\"lcp_content\"><p>Gilda G. Hillman, et al.<br \/>\nJournal for ImmunoTherapy of Cancer, January 2017 \u2013 <a href=\"http:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-016-0204-3\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/11\/AASLD-2016-poster-1868-Transgene.pdf\" title=\"TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.<\/div> <\/a><div class=\"lcp_content\"><p>Roland Kratzer, et al.<br \/>\nAASLD &amp; Hepatology, October 2016 &#8211; DOI: 10.1002\/hep.28800<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/11\/AASLD-2016-poster-1868-Transgene.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Patricia Kleinpeter, et al.<br \/>OncoImmunology, October 2016 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2016.1220467\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Patricia Kleinpeter, et al.<br \/>OncoImmunology, October 2016 \u2013 <a href=\"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2016.1220467\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/><em>Publication<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities<\/div> <div class=\"lcp_content\">\n<p><br \/>Johann Foloppe, et al.<br \/>10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada &#8211; 1-4 October 2016<br \/>Download the poster <a href=\"..\/..\/wp-content\/uploads\/2016\/10\/161005-Poster_Vancouver_VACV-intrabody.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<p>Collaboration between Transgene \u2013 HTS facility IGBMC, Illkirch \u2013 France IREBS, Illkirch, France \u2013 ICube, Strasbourg, France<\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_RCN_FCU1.pdf\" title=\"Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene<\/div> <\/a><div class=\"lcp_content\"><p>Marine Ricordel, et al.<br \/>\nXXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_RCN_FCU1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_MVA_autophagy_inhib.pdf\" title=\"Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor<\/div> <\/a><div class=\"lcp_content\"><p>Anita Spindler, et al.<br \/>\nXXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_MVA_autophagy_inhib.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies<\/div> <div class=\"lcp_content\">\n<p class=\"eplus-wrapper wp-block-paragraph\"><br>Johann Foloppe, et al.<br>XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br>Download the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_TG6002.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br><em>Poster Presentation<\/em><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/meetinglibrary.asco.org\/content\/122703?media=vm&amp;intcmp=AM15iPlanner-W eb-ViewPoster-122703\" title=\"A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF \/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF \/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy<\/div> <\/a><div class=\"lcp_content\"><p>Ghassan K. Abou-Alfa, et al.<br \/>\nASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois<br \/>\nDownload the poster <a href=\"http:\/\/meetinglibrary.asco.org\/content\/122703?media=vm&amp;intcmp=AM15iPlanner-W eb-ViewPoster-122703\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition<\/div> <div class=\"lcp_content\">\n<p><br \/>Jean Baptiste Marchand, et al.<br \/>XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016<br \/>Download the poster <a href=\"\/wp-content\/uploads\/2016\/07\/160701-Poster_Poxvirus_congress_OVV_AB_FaB_ScFv.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/><em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2016\/04\/1604-Poster-AACR-format-122-244-v2.pdf\" title=\"Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition<\/div> <\/a><div class=\"lcp_content\"><p>Jean Baptiste Marchand, et al.<br \/>\nAACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2016\/04\/1604-Poster-AACR-format-122-244-v2.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation <\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(15)00483-0\/abstract\" title=\"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nThe Lancet Oncology, December 2015, 17: 212\u201323 \u2013 <a href=\"http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(15)00483-0\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0143552\" title=\"A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates<\/div> <\/a><div class=\"lcp_content\"><p>Stephane Leung-Theung-Long, et al<br \/>\nPLOS One, November 24, 2015 DOI: 10.1371\/journal.pone.0143552 \u2013 <a href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0143552\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2015\/11\/SITC-2015-TG4010-TIME-Trial.pdf\" title=\"TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial<\/div> <\/a><div class=\"lcp_content\"><p>John Nemunaitis, et al.<br \/>\nSITC 2015, November 2015 \u2013 Abstract available on the <a href=\"http:\/\/www.immunotherapyofcancer.org\/supplements\/3\/S2\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SITC website<\/strong><\/a><br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2015\/11\/SITC-2015-TG4010-TIME-Trial.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26209840\" title=\"Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.<\/div> <\/a><div class=\"lcp_content\"><p>Ophelie Godon, et al.<br \/>\nVaccine. 2015 Aug 26;33(36):4548-53 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26209840\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/library.iaslc.org\/search?search_keyword=TG4010\" title=\"TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\n16th World Conference on Lung Cancer. September 2015, Denver, Colorado<br \/>\nDownload the poster <a href=\"http:\/\/library.iaslc.org\/search?search_keyword=TG4010\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2015\/05\/Poster-ASCO-2015_TG4010-TIME-Ph-2b-trial.pdf\" title=\"Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nASCO Annual Meeting 2015 &#8211; May 29-June 2, 2015 &#8211; Chicago, Illinois<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2015\/05\/Poster-ASCO-2015_TG4010-TIME-Ph-2b-trial.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation <\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(15)30039-8\/abstract\" title=\"TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models<\/div> <\/a><div class=\"lcp_content\"><p>Karine L\u00e9lu, et al.<br \/>\nJournal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 \u2013 <a href=\"http:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(15)30039-8\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2015\/04\/EASL2015-TG1050_presentation-PMartin_21042015.pdf\" title=\"TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models<\/div> <\/a><div class=\"lcp_content\"><p>Karine L\u00e9lu, et al.<br \/>\nEASL Liver Congress 2015, Vienna-23th April 2015<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2015\/04\/EASL2015-TG1050_presentation-PMartin_21042015.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2015\/04\/Poster-TG4010-AACR-2015-KR.pdf\" title=\"Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer<\/div> <\/a><div class=\"lcp_content\"><p>Karola Rittner, et al.<br \/>\nAACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2015\/04\/Poster-TG4010-AACR-2015-KR.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"\/wp-content\/uploads\/2015\/04\/Poster-MVA-VIRAL-PLATFORM-AACR-2015-JML.pdf\" title=\"The MVA viral platform for the treatment of cancer and chronic infectious diseases:  Clinical experience from four randomized controlled phase II studies\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>The MVA viral platform for the treatment of cancer and chronic infectious diseases:  Clinical experience from four randomized controlled phase II studies<\/div> <\/a><div class=\"lcp_content\"><p>Jean-Marc Limacher, et al.<br \/>\nAACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498.<br \/>\nDownload the poster <a href=\"\/wp-content\/uploads\/2015\/04\/Poster-MVA-VIRAL-PLATFORM-AACR-2015-JML.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.nature.com\/nrgastro\/journal\/vaop\/ncurrent\/full\/nrgastro.2015.8.html\" title=\"Viral hepatitis: HBV cure\u2014can we pin our hopes on immunotherapy ?\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Viral hepatitis: HBV cure\u2014can we pin our hopes on immunotherapy ?<\/div> <\/a><div class=\"lcp_content\"><p>Hung-Chih Yang, et al.<br \/>\nNature Reviews Gastroenterology &#038; Hepatology (2015) doi:10.1038\/nrgastro.2015.8 \u2013 <a href=\"http:\/\/www.nature.com\/nrgastro\/journal\/vaop\/ncurrent\/full\/nrgastro.2015.8.html\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=TG1050\" title=\"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.<\/div> <\/a><div class=\"lcp_content\"><p>Martin P, Dubois, et al.<br \/>\nGut. 2014 Nov 26, doi: 10.1136\/gutjnl-2014-308041 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=TG1050\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.immunotherapyofcancer.org\/content\/2\/S3\/O12\" title=\"TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nJournal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 \u2013 <a href=\"http:\/\/www.immunotherapyofcancer.org\/content\/2\/S3\/O12\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"..\/wp-content\/uploads\/2014\/09\/ESMO-2014-Poster-TG4010-TIME-Ph-2b.pdf\" title=\"TIME: A Phase 2b\/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TIME: A Phase 2b\/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.<\/div> <\/a><div class=\"lcp_content\"><p>Elisabeth Quoix, et al.<br \/>\nESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152<br \/>\nDownload the poster <a href=\"..\/wp-content\/uploads\/2014\/09\/ESMO-2014-Poster-TG4010-TIME-Ph-2b.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>here<\/strong><\/a><br \/>\n<em>Poster Presentation<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24657484\" title=\"Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.<\/div> <\/a><div class=\"lcp_content\"><p>Adrian Di Bisceglie, et al.<br \/>\nGastroenterology, 2014; Mar 18 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24657484\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24726690\" title=\"Comparative analysis of immunization schedules using a novel adenovirus \u2013 based immunotherapeutic targeting hepatitis B in na\u00efve and tolerant mouse models.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Comparative analysis of immunization schedules using a novel adenovirus \u2013 based immunotherapeutic targeting hepatitis B in na\u00efve and tolerant mouse models.<\/div> <\/a><div class=\"lcp_content\"><p>Houda Boukhebza, et al.<br \/>\nVaccine. 2014, 32(26):3256-63. \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24726690\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/link.springer.com\/article\/10.1007%2Fs13665-014-0072-6\" title=\"Immunotherapy for non &#8211; small &#8211; cell lung cancer: current approaches.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Immunotherapy for non &#8211; small &#8211; cell lung cancer: current approaches.<\/div> <\/a><div class=\"lcp_content\"><p>\nElisabeth Quoix, et al.<br \/>\nCurrent Respiratory Care Reports, 2014; 3 (1): 19-25 \u2013 <a href=\"http:\/\/link.springer.com\/article\/10.1007%2Fs13665-014-0072-6\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.immunotherapyofcancer.org\/content\/pdf\/2051-1426-1-S1-P90.pdf\" title=\"Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.<\/div> <\/a><div class=\"lcp_content\"><p>Mica\u00ebl De Meyer, et al.<br \/>\nJournal for Immunotherapy of Cancer, 2013 \u2013 <a href=\"http:\/\/www.immunotherapyofcancer.org\/content\/pdf\/2051-1426-1-S1-P90.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/onlinelibrary.wiley.com\/enhanced\/doi\/10.1002\/hep.26796\/#hep26796-sec-0009\" title=\"TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.<\/div> <\/a><div class=\"lcp_content\"><p>\nPerrine Martin, et al.<br \/>\nHepatology, 2013, (58) S1, 222A\u2013225A \u2013 <a href=\"http:\/\/onlinelibrary.wiley.com\/enhanced\/doi\/10.1002\/hep.26796\/#hep26796-sec-0009\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813603931\" title=\"Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.<\/div> <\/a><div class=\"lcp_content\"><p>Houda Boukhebza, et al.<br \/>\nJournal of Hepatology, 2013, (58), Supplement 1, S161 \u2013 <a href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813603931\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813601324\" title=\"130 \u2013 A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>130 \u2013 A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.<\/div> <\/a><div class=\"lcp_content\"><p>Perrine Martin, et al.<br \/>\nJournal of Hepatology, 2013, (58), Supplement 1, S57\u2013S58. \u2013 <a href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827813601324\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/31\/15_suppl\/4122?sid=e16b8da1-8ce1-4b77-8ecd-372140abfe94\" title=\"Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)<\/div> <\/a><div class=\"lcp_content\"><p>J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn<br \/>\n<em>Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122)<\/em><br \/>\n<span style=\"display:block\">[Publication]<\/span><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/31\/15_suppl\/3608?sid=e16b8da1-8ce1-4b77-8ecd-372140abfe94\" title=\"Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)<\/div> <\/a><div class=\"lcp_content\"><p>J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, J. Lee, W.K. Kang, J.O. Park, A. Pelusio, C. Breitbach, D.H. Kirn<br \/>\n<em>Journal of clinical Oncology, 2013, 31, (suppl; abstr 3608)<\/em><br \/>\n<span style=\"display:block\">[Publication]<\/span><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23677592\" title=\"Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans<\/div> <\/a><div class=\"lcp_content\"><p>\nMi Kyung Kim, et al.<br \/>\nScience Translational Medicine. 2013 May 15;5(185):185ra63 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23677592\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Randomized+dose-finding+clinical+trial+of+oncolytic\" title=\"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer<\/div> <\/a><div class=\"lcp_content\"><p>Jeong Heo, et al.<br \/>\nNature Medicine, 2013 (3):329-36. doi: 10.1038\/nm.3089. Epub 2013 Feb 10. \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Randomized+dose-finding+clinical+trial+of+oncolytic\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><li><a class=\"count\" onclick=\"count()\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23496666\" title=\"Therapeutic cancer vaccines in the treatment of non-small cell lung cancer\"><div class='publiOnglet'> <\/div><div class='catlistTitle'>Therapeutic cancer vaccines in the treatment of non-small cell lung cancer<\/div> <\/a><div class=\"lcp_content\"><p>\nJean-Marc Limacher, et al.<br \/>\nExpert Review of Vaccines, 2013; 12(3): 263-270 \u2013 <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23496666\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Download the article<\/strong><\/a><br \/>\n<em>Publication<\/em><\/p>\n<\/div><\/li><\/ul>\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n\n<\/div>\n<\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Publications &nbsp; Classement par produit &nbsp; \u00a0 Classement par date\u00a0 \u00a0<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-26788","page","type-page","status-publish","hentry","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"Publications &nbsp; Classement par produit &nbsp; \u00a0 Classement par date\u00a0 \u00a0","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages\/26788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=26788"}],"version-history":[{"count":17,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages\/26788\/revisions"}],"predecessor-version":[{"id":40525,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/pages\/26788\/revisions\/40525"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=26788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}